Edwards Lifesciences Toekomstige groei
Future criteriumcontroles 1/6
Edwards Lifesciences zal naar verwachting groeien in winst en omzet met respectievelijk 1.9% en 4.8% per jaar. De winst per aandeel zal naar verwachting groeien met 2.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 23.1% zijn.
Belangrijke informatie
1.9%
Groei van de winst
2.9%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 17.1% |
| Inkomstengroei | 4.8% |
| Toekomstig rendement op eigen vermogen | 23.1% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 04 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11
Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 6,540 | 1,603 | 1,526 | 1,773 | 26 |
| 12/31/2025 | 5,926 | 1,493 | 1,435 | 1,835 | 30 |
| 12/31/2024 | 5,837 | 1,387 | 1,415 | 1,922 | 30 |
| 9/30/2024 | 6,315 | 1,567 | 490 | 806 | N/A |
| 6/30/2024 | 6,204 | 1,540 | 552 | 866 | N/A |
| 3/31/2024 | 6,114 | 1,428 | 251 | 528 | N/A |
| 12/31/2023 | 6,005 | 1,402 | 630 | 896 | N/A |
| 9/30/2023 | 5,092 | 1,288 | 775 | 1,042 | N/A |
| 6/30/2023 | 5,168 | 1,296 | 669 | 940 | N/A |
| 3/31/2023 | 5,279 | 1,451 | 972 | 1,239 | N/A |
| 12/31/2022 | 5,382 | 1,522 | 953 | 1,218 | N/A |
| 9/30/2022 | 5,364 | 1,459 | 1,040 | 1,309 | N/A |
| 6/30/2022 | 5,355 | 1,455 | 1,261 | 1,531 | N/A |
| 3/31/2022 | 5,357 | 1,539 | 1,428 | 1,725 | N/A |
| 12/31/2021 | 5,233 | 1,503 | 1,402 | 1,732 | N/A |
| 9/30/2021 | 5,095 | 1,477 | 1,409 | 1,758 | N/A |
| 6/30/2021 | 4,925 | 1,462 | 1,050 | 1,443 | N/A |
| 3/31/2021 | 4,474 | 851 | 717 | 1,148 | N/A |
| 12/31/2020 | 4,386 | 823 | 647 | 1,054 | N/A |
| 9/30/2020 | 4,369 | 794 | 692 | 1,057 | N/A |
| 6/30/2020 | 4,322 | 744 | 941 | 1,279 | N/A |
| 3/31/2020 | 4,484 | 1,108 | 1,087 | 1,389 | N/A |
| 12/31/2019 | 4,348 | 1,047 | 905 | 1,183 | N/A |
| 9/30/2019 | 4,152 | 774 | 809 | 1,073 | N/A |
| 6/30/2019 | 3,964 | 725 | 705 | 978 | N/A |
| 3/31/2019 | 3,821 | 765 | 523 | 777 | N/A |
| 12/31/2018 | 3,723 | 722 | 685 | 927 | N/A |
| 9/30/2018 | 3,634 | 712 | 754 | 998 | N/A |
| 6/30/2018 | 3,549 | 657 | N/A | 966 | N/A |
| 3/31/2018 | 3,447 | 560 | N/A | 1,024 | N/A |
| 12/31/2017 | 3,435 | 584 | N/A | 1,001 | N/A |
| 9/30/2017 | 3,315 | 745 | N/A | 838 | N/A |
| 6/30/2017 | 3,232 | 716 | N/A | 733 | N/A |
| 3/31/2017 | 3,150 | 657 | N/A | 726 | N/A |
| 12/31/2016 | 2,964 | 570 | N/A | 704 | N/A |
| 9/30/2016 | 2,867 | 552 | N/A | 607 | N/A |
| 6/30/2016 | 2,743 | 528 | N/A | 604 | N/A |
| 3/31/2016 | 2,601 | 515 | N/A | 584 | N/A |
| 12/31/2015 | 2,494 | 495 | N/A | 550 | N/A |
| 9/30/2015 | 2,441 | 463 | N/A | 539 | N/A |
| 6/30/2015 | 2,433 | 440 | N/A | 349 | N/A |
| 3/31/2015 | 2,391 | 874 | N/A | 957 | N/A |
| 12/31/2014 | 2,323 | 811 | N/A | 1,022 | N/A |
| 9/30/2014 | 2,241 | 777 | N/A | 1,040 | N/A |
| 6/30/2014 | 2,129 | 759 | N/A | 1,160 | N/A |
| 3/31/2014 | 2,071 | 306 | N/A | 511 | N/A |
| 12/31/2013 | 2,046 | 389 | N/A | 473 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei van EW ( 1.9% per jaar) ligt onder de spaarquote ( 2.6% ).
Winst versus markt: De winst van EW ( 1.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).
Hoge groeiwinsten: De winst van EW zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van EW ( 4.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van EW ( 4.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen EW zal naar verwachting over 3 jaar hoog zijn ( 23.1 %)